Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: Relationship between MMP-10 and LV remodelling

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 4, 2011, Pages 773-782

  Wei, Yingjie ^a   Cui, Chuanjue ^a   Lainscak, Mitja ^b,c   Zhang, Xiaoling ^a   Li, Jun ^a   Huang, Jie ^a   Zhang, Hao ^a   Zheng, Zhe ^a   Hu, Shengshou ^a  

^a FUWAI HOSPITAL   (China)

^b Division of Cardiology   (Slovenia)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Heart failure; Left ventricular remodelling; Metalloproteinases

Indexed keywords

MATRILYSIN; MMP10 PROTEIN, HUMAN; MMP7 PROTEIN, HUMAN; SOMATOMEDIN B; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TISSUE INHIBITOR OF METALLOPROTEINASE-4;

ADOLESCENT; ANIMAL; ARTICLE; BLOOD; CHILD; CONGESTIVE CARDIOMYOPATHY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FEMALE; HEART FAILURE; HEART MUSCLE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REPRODUCIBILITY;

ADOLESCENT; ANIMALS; CARDIOMYOPATHY, DILATED; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; MYOCARDIUM; RATS; REPRODUCIBILITY OF RESULTS; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

RATTUS;

EID: 79955662598     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01049.x     Document Type: Article

References (29)

1. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007; 87: 1285-342.
2. Gunja-Smith Z, Morales AR, Romanelli R, et al Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 1996; 148: 1639-48.
3. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and their TIMPs. Cardiovasc Res. 2006; 69: 562-73.
4. Yoon SO, Park SJ, Yun CH, et al Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 2003; 36: 128-37.
5. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002; 90: 520-30.
6. Thomas CV, Coker ML, Zellner JL, et al Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998; 97: 1708-15.
7. Spinale FG, Coker ML, Heung LJ, et al A matrix metallproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000; 102: 1944-9.
8. Fedak PWM, Altamentova SM, Weisel RD, et al Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol. 2003; 284: H626-34.
9. Sen-Chowdhry S, Syrris P, Ward D, et al Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007; 115: 1710-20.
10. Seeland U, Selejan S, Engelhardt S, et al Interstitial remodeling in β1-adrenergic receptor transgenic mice. Basic Res Cardiol. 2007; 102: 183-93.
11. Jeyaseelan R, Poizat C, Baker RK, et al A Novel Cardiac-Restricted Target for Doxorubicin. J Biol Chem. 1997; 272: 22800-08.
12. Tyagi SC, Kumar S, Voelker DJ, et al Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem. 1996; 63: 185-98.
13. Boixe C, Fontaine V, Rucker-Martin C, et al Fibrosis of the Left Atria During Progression of Heart Failure Is Associated With Increased Matrix Metalloproteinases in the Rat. J Am Coll Cardiol. 2003; 42: 336-44.
14. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999; 274: 21491-4.
15. Chang S, Young BD, Li S, et al Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 2006; 126: 321-34.
16. Rodriguez JA, Orbe J, de Lizarrondo SM, et al Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Frontiers in Bioscience. 2008; 13: 2916-21.
17. Ogata T, Shibamura H, Tromp G, et al Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg. 2005; 41: 1036-42.
18. Tziakas DN, Chalikias GK, Papaioakeim M, et al Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol. 2005; 96: 1449-51.
19. Levine B, Kalman J, Mayer L, et al Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New Engl J Med. 1990; 323: 236-41.
20. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res. 1999; 42: 162-72.
21. Lefebvre V, Peeters-Joris C, Vaes G. Production of gelatin-degrading matrix metalloproteinases ("type IV collagenases'') and inhibitors by articular chondrocytes during their dedifferentiation by serial subcultures and under stimulation by interleukin-1 and tumor necrosis factor alpha. Biochim Biophys Acta. 1991; 1094: 8-18.
22. Kluge A, Zimmermann R, Munkel B, et al Insulin-like growth factor II is an experimental stress inducible gene in a porcine model of brief coronary occlusions. Cardiovasc Res. 1995; 29: 708-16.
23. Chang MH, Kuo WW, Chen RJ, et al IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells. J Mol Endocrinol. 2008; 41: 65-74.
24. Ewton DZ, Falen SL, Florini JR. The type II insulin-like growth factor (IGF) receptor has low affinity for IGF-1 analogs: pleiotropic actions of IGFs on myoblasts are apparently mediated by the type I receptor. Endocrinology. 1987; 120: 115-23.
25. Froesch ER, Schmid C, Schwander J, et al Action of insulinlike growth factors. Annu Rev Physiol. 1985; 47: 443-67.
26. Vanhoutte D, Schellings M, Pinto Y, et al Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res. 2006; 69: 604-13.
27. Fedak PW, Smookler DS, Kassiri Z, et al TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation. 2004; 110: 2401-09.
28. Klotz S, Foronjy RF, Dickstein ML, et al Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation. 2005; 112: 364-74.
29. Peterson JT, Hallak H, Johnson L, et al Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001; 103: 2303-9.